A privately held biopharmaceutical company based in Tokyo, Japan, Anaeropharma Science was established in 2004 to pioneer the development of novel therapeutics to target such a hypoxic environment in solid cancers based on its proprietary platform technology, i-DPS. » Read full article

Our goal is to create more effective and safer therapies based on our core platform technology, i-DPS. The technology has the potential for broad applications in oncology and as well as other hypoxic lesions related diseases.
» Read full article